IP and Biopharma:
Separating Myth from Reality
When we think about prescription medicines, we often see only the final product: a small pill, a vial of liquid, or an autoinjector. What remains invisible is the long journey of problem-solving, inevitable setbacks, and further innovation that turns a promising molecule into a medicine patients can actually use.
Patents help make that journey possible. They secure investment not only in the original active ingredient, but also in later inventions, both before and after approval, that can help advance or improve formulation, delivery, dosing, manufacturing, new uses, and patient administration.
In recent years, however, pharmaceutical patents have become a target in healthcare policy debates. Critics often claim that drug companies use patents primarily to block generic and biosimilar competitors and maintain high prices. But these claims largely rest on flawed proxies and misleading inferences, including the assumption that patent counts or later expiration dates prove delayed competition.
Drug affordability is a legitimate concern, and one worth taking seriously on its own terms. But policies aimed at lowering prices should be grounded in evidence about how competition actually occurs and how innovation is financed.
Across the series, we examine:
-
Why later patents on improvements to a medicine do not “extend” the original patent protection, but cover separate inventions that can be challenged, designed around, or avoided by competitors.
-
Why counting patents or pointing to later expiration dates on related patents does not show that competition was actually delayed.
-
How the real-world period before generic entry has averaged roughly 13 to 14 years, far shorter than claims based on patent counts and latest expiration dates predict.
-
How later inventions, including new formulations, delivery systems, doses, uses, and manufacturing improvements, can address meaningful patient needs without blocking generic competition for the original product.
-
How public research and private investment work together, and how that division of labor is often misunderstood.
By separating myth from reality in pharmaceutical patent debates, we can pursue policies that balance innovation and access without sacrificing either.
Pharmaceutical "Patent Thickets"
Pharmaceutical patents have become a focal point of debate, often portrayed as tools used by companies to stifle competition and maintain high prices. However, the reality is more complex: drug patents protect genuine scientific solutions that make medicines safer, more effective, and more accessible for patients. This paper challenges the “patent thicket” narrative by presenting evidence that multiple patents on a single drug reflect cumulative innovation rather than anti-competitive behavior—and that generic competition continues to arrive predictably within 13–14 years of approval.
As with a car, phone, or even a golf club, a medicine represents a series of inventions, each of which may be patented, including improvements that may be added over time. Creating a medicine does not happen in a single Eureka! moment, but over a long process as scientists solve problems.
What people experience as a “medicine” or drug “product” is likely a bundle of inventions.
Each patent represents a particular invention that solves a specific scientific problem encountered during drug development – from improving absorption to enhancing stability –not strategic extensions of monopoly power. These innovations are needed to address the problems that otherwise cause 90% of drug candidates to fail.
Patents protect solutions to problems encountered and solved during drug development.
Despite critics’ claims, the effective market exclusivity period has remained stable at 13-14 years for decades, regardless of patent count. Generic manufacturers routinely navigate patent landscapes, introducing competition on a predictable timeline.
Multiple patents don’t delay generic competition.
Most of the drugs (61%) currently approved for marketing no longer have any patents, a fact that reminds us that all patents expire and all generic drugs start life as patented drugs. Of those drugs with patents still in force, most have fewer than four. Leading companies in other sectors obtain ten times more patents per R&D dollar than pharmaceutical companies.
Pharmaceutical patenting is moderate compared to other industries.
Restricting the number of patents that can be obtained or enforced would hinder important advancements that minimize side effects and broaden treatment options, without fostering increased generic competition.
Patent caps would harm innovation without helping competition.
The generic industry is thriving.
Generics now fill 90% of all U.S. prescriptions (up from 13% in 1984), demonstrating that the current patent system successfully balances innovation incentives with competition and patient access.
Scientists must solve myriad challenges to transform a promising molecule into a safe and effective drug that can receive regulatory approval.
60% of medicines in the market have no patent, and biopharma patenting is less intensive than in other sectors.
Critics argue that drug companies create “patent thickets,” dense webs of overlapping patents on a single medicine, to block generic competition and keep drug prices high. The evidence does not support the argument. Proposals such as the ETHIC Act would cap the number of patents an innovator can assert.
Read the complete Patent Thickets infopack
Pharmaceutical Patent “Evergreening”
Critics argue that brand-name drug companies “evergreen” their patents, strategically manipulating the patent system to inappropriately extend market exclusivity, delay generic entry and maintain high prices. In reality, patents cannot be extended indefinitely. They last 20 years from filing, with narrow and specific adjustments to this term only for government-caused delays. Moreover, later patents on drug improvements don’t extend earlier patents or block the generic entry of drug products using the inventions that were embodied in the original version of the drug. The “evergreening” metaphor obscures these legal realities and misdirects policy discussions. This series of papers tackles common myths about patents and market exclusivity for innovative medicines.
Reality Check: Evergreening
Beyond the patent on the original molecule, there are essentially two types of patents that cover further innovations on a pharmaceutical product: patents on innovations that occur before regulatory approval (to develop the original molecule into a safe and effective drug that can receive regulatory approval), and patents on innovations that occur after approval (to improve efficacy, user experience, patient benefits, or extend benefits to more patients).
Innovators patent the original molecule and additional inventions that occur before and after regulatory approval.
Later-filed patents protect distinct inventions and do not extend earlier patents.
Later-filed patents on improvements to existing medicines protect distinct inventions that make medicines safer, more effective, or easier to use. They can be crucial to making a compound into a workable drug, or to improving an existing medicine. These patents do not extend the original patent, and they do not block copying of the original product once its patents expire. Studies consistently find that later patents don’t delay generic entry.
Critics who treat every patent related to a drug as preventing entry of any generic version misinterpret how generics work. Generics copy specific approved drug products, and the effect of patents on generic entry depends only on the patents covering that specific product. Treating the initial compound patent as the only legitimate patent is like saying only the engine patent matters for a car.
Later-filed patents do not prevent generics from making the original product once the earlier patents expire.
U.S. market exclusivity periods have been stable at 13-14 years for decades, contrary to “evergreening" predictions.
When tested against real data, “evergreening” claims consistently fail; one study found that predictions are wrong by an average of 7 years. Despite predictions of extended monopolies, U.S. market exclusivity periods have remained stable at about 13-14 years since the 1980s.
Generics enter the market quickly once patents expire, benefitting from legal advantages such as abbreviated approval pathways, incentives to challenge patents, automatic substitution laws, and a patent infringement safe harbor for activities associated with regulatory approval. Today, generics now fill over 90% of U.S. prescriptions.
Generics enter the market and capture market share quickly upon patent expiration.
Patents may be extended to compensate for government delays - but not indefinitely or repeatedly.
Patents expire 20 years from the filing date, save for Patent Term Adjustments (PTA) and Patent Term Extensions (PTE). These adjustments compensate for delays in patent examination and regulatory review, and they are the product of specific mathematical formulas with caps. They cannot extend patents indefinitely or repeatedly.
U.S. market exclusivity periods for medicines have remained stable at about 13-14 years for decades.
Critics claim that drug companies “evergreen” their patents, using later filings to extend exclusivity on medicines for decades and block generic competition. The evidence does not support the claim.
Read the complete Evergreening infopack
The Value of Continuous Innovation
Biopharmaceutical companies continue innovating, seeking to expand the use of an approved drug to new patient populations and different diseases, develop better delivery systems, and improve formulations. This ongoing work, known as continuous innovation, is a defining feature of the biopharmaceutical industry. It often builds on earlier research, becoming feasible and clinically actionable after a medicine has been approved for use in patients by regulators.
A common question is: Why is the initial version of a medicine not already optimized in every respect? The answer lies in how science progresses. The medicine that reaches approval reflects the best that current knowledge and technology allow at that time.
Approval opens new possibilities, as science advances and clinical experience reveals practical challenges, unmet needs, and opportunities to deliver greater value to patients and healthcare systems. Once a medicine has been shown to be safe and effective, it becomes a proven and powerful foundation for further research and discovery.
Post-approval R&D requires investment and carries risk, and it is not guaranteed to succeed. Post-approval inventions that solve problems may be patentable. These patents reflect new work, not extensions of old protections.
Continuous innovation delivers great value to patients and society, making treatment easier to use, expanding access to new patients, and reducing burdens on healthcare systems. This series of papers illustrates how continuous innovation works and the investments in research and development required, including case studies of continuous innovation that delivered new indications, delivery systems, and combination therapies.
Reality Check: Continuous Innovation
Reality Check: The Value of Continuous Innovation
Key Insights: Continuous Innovation
Innovators are incentivized to maximize the therapeutic potential of a drug for other disease and patient populations during their period of market exclusivity. And the opportunity to patent improvements helps to secure and encourage investments in post-approval R&D.
A medicine shown to be safe and effective becomes a powerful foundation for further research and discovery.
Continuous innovation involves substantial uncertainty, technical difficulty, and additional resources. It often requires investment in costly phase III trials, with no guarantees that investments will lead to an approved treatment.
Post-approval R&D requires investments and carries risk.
Read the complete Continuous Innovation infopack
Post-approval R&D can meaningfully improve patient experience, expand access, and reduce burdens on healthcare systems. In some therapeutic areas, half of all treatment options originated not from new molecules but from continued research on existing ones. Two-thirds of cancer drugs approved in the U.S. over the past decade later gained at least one additional indication.
Continuous innovation adds great value for patients and society.
The first version of a medicine to reach approval reflects the best knowledge and technology at that time. Approval opens new possibilities as science advances and clinical experience highlights opportunities to deliver greater value to patients and healthcare systems.
Innovation doesn’t stop once a new drug becomes first available to patients.
Scientific advancement is iterative. The nature of drug discovery, development, and clinical trials often means the learning and inventive process occur over time. Post-approval inventions that solve problems may be patentable. These patents reflect new work and do not extend earlier patents.
Post-approval improvements, and related patents, arrive later due to how scientific research unfolds.
Patents on post-approval improvements to drugs do not block generics.
Patents on improvements do not prevent generic manufacturers from marketing the medicine in its original form, for the original approved use, once the relevant patents expire. For more information about post-approval patents and generic competition, see our papers on “evergreening” and “patent thickets”.
© 2026 IPPI and Innovation Council
Sponsored by Interpat